Skip to main content
Premium Trial:

Request an Annual Quote

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

NEW YORK ─ Hologic said on Thursday that it has inked an agreement to acquire Mobidiag, a developer of molecular diagnostic tests and instrumentation, for approximately $795 million.

The deal includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million, Marlborough, Massachusetts-based Hologic said. It added it anticipates financing the deal with cash on hand and borrowing from an existing line of credit.

In 2020, privately held Mobidiag booked approximately $42 million in revenue. The Espoo, Finland-based company develops and markets tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections. Its automated Amplidiag and Novodiag instruments provide turnaround times ranging from 50 minutes to two hours.

Novodiag combines real-time PCR and microarrays to provide high-level multiplexing that detects multiple pathogens in a single sample, Hologic said, adding that it intends to invest in assay development for the platform.

Last month, Mobidiag announced it had received the CE mark for its Amplidiag Resp-4 molecular diagnostic test for the detection of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus.

Hologic said it anticipates that the acquisition, which it expects to close early in the fourth quarter of fiscal 2021, would be approximately $0.10 dilutive to its non-GAAP earnings per share in fiscal 2022, slightly dilutive in 2023, and accretive thereafter.

Tuomas Tenkanen, Mobidiag’s CEO, said in a statement that under Hologic, the firm "will continue to be committed to its existing customer base in Europe, including our home markets of Finland, France, Sweden, and UK. … Hologic’s commercial expertise, scale, and investment strength will accelerate the broader market adoption of our products."

The deal with Mobidiag would represent the third acquisition of a molecular diagnostics firm by Hologic in recent months. In March, it acquired Diagenode, a European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million. That quickly followed Hologic's completion of the acquisition of Biotheranostics, a developer of diagnostic, prognostic, and predictive cancer tests, for approximately $230 million.

"One of our key goals is to use our strong cash flow to create a larger, faster-growing company for a post-pandemic world," Steve MacMillan, Hologic's chairman, president, and CEO said in a statement. "Mobidiag provides an exceptional new growth platform, which will generate long-term value by enabling us to enter the acute care market, which is expected to roughly double in the next five years, with a differentiated, highly competitive solution."

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.